Calliditas Therapeutics AB (publ) (CALT) Financial Analysis & Valuation | Quarter Chart
Calliditas Therapeutics AB (publ) (CALT)
CALTPrice: $40
Fair Value: 🔒
🔒score
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide ... more
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifyin... more
Description
Shares
| Market Cap | $2.15B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | SE | CEO | Renee Aguiar-Lucander |
| IPO Date | 2020-06-05 | CAGR | 1.66% |
| Employees | 222 | Website | www.calliditas.se |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CALT chart loading...
Fundamentals
Technicals
| Enterprise Value | $11.21B | P/E Ratio | -22.73 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 9.31 | P/B Ratio | 33.34 |
| P/CF Ratio | -25.68 | P/FCF Ratio | -25.12 |
| EPS | $-1.76 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 39.27% | Gross Margin | 0.94% |
| Operating Margin | -0.32% | Profit Margin | -0.39% |
| ROE | -0.85% | ROA | -0.25% |
| ROCE | -0.26% | Current Ratio | 3.13 |
| Quick Ratio | 3.08 | Cash Ratio | 2.39 |
| Debt/Equity | 2.92 | Interest Coverage | -3.36 |
| Altman Z Score | 1.51 | Piotroski Score | 2 |